載入中
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
前收盤價
US$39.06
−US$0.17 · -0.43%
盤中時間採用ET。市場資料可能有所延遲。
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
日內區間
目前US$39.06
52週區間
目前US$39.06
盤中時間採用ET。市場資料可能有所延遲。
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
日內區間
目前US$39.06
52週區間
目前US$39.06
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 226.6萬 USD | — | — | — | — |
| 毛利 | −226.6萬 USD | — | — | — | — |
| 研究與開發 | 1.51億 USD | 1.27億 USD | 9090.5萬 USD | 5403.2萬 USD | 3218.9萬 USD |
| 銷售、一般及管理費用 | 4001.7萬 USD | 3186.6萬 USD | 2345.2萬 USD | 1762.6萬 USD | 1102.6萬 USD |
| 營業費用 | 1.89億 USD | 1.59億 USD | 1.14億 USD | 7165.8萬 USD | 4321.5萬 USD |
| 利息收入 | 2361.1萬 USD | 2501.9萬 USD | 1419.4萬 USD | 266.4萬 USD | 40.2萬 USD |
| 利息支出 | — | — | — | 401.8萬 USD | — |
| 折舊和攤銷 | 226.6萬 USD | 229萬 USD | 173.2萬 USD | 53.8萬 USD | 27.2萬 USD |
| 營業利益 | −1.91億 USD | −1.59億 USD | −1.14億 USD | −7165.8萬 USD | −4321.5萬 USD |
| 淨利 | −1.68億 USD | −1.34億 USD | −1億 USD | −6764萬 USD | −4281.3萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.22億0.01%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM7399.38萬0.09%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF3656.63萬0.04%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO2591.37萬0.19%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB2483.43萬0.24%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO1717.14萬0.09%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA1690.98萬0.08%218.24億 USD0.03%US$32.79+0.40%
iShares U.S. Pharmaceuticals ETFIHE1112.23萬0.73%15.52億 USD0.37%US$100.09+1.24%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
